IVBM All Coverage

At our recent Institute for Value-Based Medicine® event in Boston, Hari Deshpande, MD, Yale Cancer Center, presented on predictive biomarkers in sarcomas.

Miriam Godwin, CMMI, National Kidney Foundation, touches on the gaps in kidney care that public policy can address, as well as the importance of thinking about the long-term benefits of value-based care.

Ticiana Leal, MD, Winship Cancer Institutes, explains the importance of biomarker testing and multidisciplinary conversations while caring for patients with early-stage non–small cell lung cancer (NSCLC).

In this interview from our Institute for Value-Based Medicine® event in Boston, we speak with Michael Hassett, MD, MPH, Dana-Farber Cancer Institute, on the clinical significance and cost implications of HER2 in the breast cancer space.

The theme of our inaugural regional Institute for Value-Based Medicine® event in Boston was, “Elevating Value in Cancer Care,” and one of the 4 panel discussions focused on the important contributions of pharmacists and the practice of pharmacy to the oncology space.

Linda Bosserman, MD, PhD, FASCO, FACP, of City of Hope, discusses the implementation of cutting-edge cancer treatments, emphasizing the need for effective information sharing and collaboration to improve cancer care access for diverse populations.

Andrew Leitner, MD, of City of Hope, discusses the challenges of integrating supportive care into cancer treatment and proposes solutions to improve access for patients from underserved communities.

Linda Bosserman, MD, PhD, FASCO, FACP, of City of Hope, emphasizes the need for a sustainable health care system that balances cost with care so patients can achieve the best survival and quality of life after a cancer diagnosis.

Strategies for integrated delivery networks (IDNs) to manage rising biologic medication costs while ensuring financial sustainability and patient outcomes are discussed during an interview with Elie M. Bahou, PharmD, MBA, senior vice president and system chief pharmacy officer at Providence.

JT Lew, PharmD, MBA, managed care pharmacist at MultiCare Health System, spoke to the impacts of processes such as prior authorization and step therapy requirements in the realm of multiple sclerosis (MS).

Linda Bosserman, MD, PhD, FASCO, FACP, of City of Hope, highlights challenges in cancer care, focusing on improving access to accurate diagnoses and treatments, promoting patient-centered approaches, and fostering collaboration to achieve better outcomes.

Joseph Alvarnas, MD, of City of Hope, discusses how he envisions the future of cancer care over the next decade.

Joseph Alvarnas, MD, of City of Hope, recaps yesterday's Institute for Value-Based Medicine® (IVBM) event on value-based oncology care, emphasizing patient-centered approaches and how attendees can apply these insights in their daily practice.

Dax Kurbegov, MD, senior vice president of Sarah Cannon Cancer Network, discussed divides between payers, health systems, and oncology care providers, as well as the impacts these divides can have on patients.

Sophia Humphreys, PharmD, director of formulary management at Sutter Health, discusses how group purchasing organizations (GPOs) influence integrated delivery networks (IDNs) and hospitals in making formulary decisions, including the adoption of biosimilars.

Ticiana Leal, MD, associate professor and director of the Thoracic Medical Oncology Program in the Department of Hematology and Medical Oncology at Emory University School of Medicine, discusses the latest advances in perioperative non–small cell lung cancer (NSCLC) treatment.

JT Lew, PharmD, MBA, highlights that the primary challenges for patients with multiple sclerosis (MS) in accessing prescribed medications include dealing with the shock of the diagnosis, navigating complex health plan benefits and out-of-pocket costs, and experiencing delays due to insurance barriers.

Jason Romancik, MD, a board-certified hematologist at Emory Winship Cancer Institute, discusses the current treatment landscape in aggressive lymphoma and drivers of high care costs.

While it can seem overwhelming or difficult to decide where to start addressing racial and ethnic disparities in health care, the key is to focus on a manageable area that can be built upon.

Alex Jahangir, MD, MMHC, of Vanderbilt University Medical Center, discusses innovative technologies to combat burnout and improve specialty care.

Katherine Baker, MD, MMHC, of Tennessee Oncology, highlights the need for physician-payer collaboration to tackle challenges and drive innovation in specialty care.

Fahad Tahir, MAS, MBA, FACHE, of Ascension St Thomas, discusses health system innovation and entrepreneurship, highlighting specialty care advancements and leadership strategies for fostering innovation.

Katherine Coerver, MD, PhD, FAAN, neurologist, Rocky Mountain Neurology, shares insights on advancements and challenges in neurological care.

Samyukta Mullangi, MD, MBA, of Tennessee Oncology and Thyme Care, discusses the future of specialty value-based care and how attendees can apply what they learned at the Institute for Value-Based Medicine event on August 22.

Demetria Smith-Graziani, MD, MPH, Emory University School of Medicine, explained biological and structural obstacles to equitable breast cancer outcomes and care across racial and ethnic groups.

At an Institute for Value-Based Medicine® (IVBM) event cohosted by The American Journal of Managed Care®, experts discussed efforts to implement obesity management science into practice.

Maria Amaya, MD, PhD, University of Colorado School of Medicine, explores discrepancies between real-world data and clinical trial outcomes, as well as her experience ensuring the reliability of real-world analysis.

Andrew Hantel, MD, Dana-Farber Cancer Institute, discusses factors contributing to disparities in oncology clinical trial enrollment.